Nevro (NVRO)
(Real Time Quote from BATS)
$5.18 USD
+0.35 (7.25%)
Updated Aug 8, 2024 10:04 AM ET
4-Sell of 5 4
D Value D Growth A Momentum C VGM
Nevro (NVRO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$14.71 | $40.00 | $8.20 | 204.55% |
Price Target
Based on short-term price targets offered by 13 analysts, the average price target for Nevro comes to $14.71. The forecasts range from a low of $8.20 to a high of $40.00. The average price target represents an increase of 204.55% from the last closing price of $4.83.
Analyst Price Targets (13)
Broker Rating
Nevro currently has an average brokerage recommendation (ABR) of 3.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 15 brokerage firms. The current ABR compares to an ABR of 3.27 a month ago based on 15 recommendations.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/NVRO.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 9 | 10 | 10 | 10 | 11 |
Sell | 2 | 2 | 2 | 2 | 2 |
Strong Sell | 4 | 2 | 2 | 2 | 1 |
ABR | 3.67 | 3.27 | 3.27 | 3.27 | 3.13 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/7/2024 | JMP Securities | David L Turkaly | Strong Buy | Hold |
8/7/2024 | Piper Sandler | Adam C Maeder | Strong Sell | Strong Sell |
8/7/2024 | Wells Fargo Securities | Nathan Treybeck | Hold | Strong Sell |
5/22/2024 | Not Identified | Not Identified | Hold | Strong Sell |
5/8/2024 | Truist Securities | Richard Newitter | Hold | Hold |
5/8/2024 | Canaccord Genuity | William J Plovanic | Hold | Hold |
5/7/2024 | William Blair | Brandon Vazquez | Hold | Hold |
4/15/2024 | Not Identified | Not Identified | Hold | Hold |
4/11/2024 | Mizuho SecuritiesUSA | Anthony Petrone | Hold | Hold |
2/22/2024 | Robert W. Baird & Co. | David Rescott | Hold | Hold |
2/22/2024 | Not Identified | Not Identified | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.67 |
ABR (Last week) | 3.27 |
# of Recs in ABR | 15 |
Average Target Price | $14.71 |
LT Growth Rate | 32.10% |
Industry | Medical - Instruments |
Industry Rank by ABR | 106 of 253 |
Current Quarter EPS Est: | -0.56 |